🔹 Revenue: $5.10B (Est. $5.081B) 🟢; UP +6% YoY; Organic +4% YoY
🔹 Adjusted EPS: $1.07 (Est. $1.05) 🟢
Guidance
🔹 Raises lower end of FY25 Adjusted EPS range; reaffirms all other FY25 metrics
Segment Results (Q3)
Imaging
🔹 Revenue: $2,349M; UP +5% YoY; Organic +4% YoY
🔹 EBIT: $240M; Margin: 10.2% (↓ 260 bps YoY)
Advanced Visualization Solutions
🔹 Revenue: $1,301M; UP +7% YoY; Organic +6% YoY
🔹 EBIT: $271M; Margin: 20.9% (↑ 180 bps YoY)
Patient Care Solutions
🔹 Revenue: $731M; DOWN -6% YoY; Organic -7% YoY
🔹 EBIT: $27M; Margin: 3.7% (↓ 680 bps YoY)
Pharmaceutical Diagnostics
🔹 Revenue: $749M; UP +20% YoY; Organic +10% YoY
🔹 EBIT: $220M; Margin: 29.4% (↓ 150 bps YoY)
Other Key Q3 Metrics:
🔹 Adjusted EBIT Margin: 14.8% (vs. 16.3% LY; tariff headwind)
🔹 Net Income: $446M; Net Margin: 8.7%
🔹 Book-to-Bill: 1.06x; Organic Orders: UP +6% YoY
🔹 Cash From Ops: $593M; Free Cash Flow: $483M
CEO Commentary
🔸 “We delivered robust orders with growth across all segments… Revenue performance was ahead of expectations.”
🔸 “Increased R&D and focus on lean set us up to accelerate top and bottom line growth.”